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Abstract
Background: Neural tube defects (NTDs) result from failure of neural tube clo-
sure during embryogenesis. These severe birth defects of the central nervous sys-
tem include anencephaly and spina bifida, and affect 0.5–2 per 1,000 pregnancies
worldwide in humans. It has been demonstrated that acetylation plays a pivotal
role during neural tube closure, as animal models for defective histone
acetyltransferase proteins display NTDs. Acetylation represents an important
component of the complex network of posttranslational regulatory interactions,
suggesting a possible fundamental role during primary neurulation events. This
study aimed to assess protein acetylation contribution to early patterning of the
central nervous system both in human and murine specimens.
Methods: We used both human and mouse (Cited2−/−) samples to analyze the
dynamic acetylation of proteins during embryo development through immuno-
histochemistry, western blot analysis and quantitative polymerase chain reaction.
Results: We report the dynamic profile of histone and protein acetylation sta-
tus during neural tube closure. We also report a rescue effect in an animal
model by chemical p53 inhibition.
Conclusions: Our data suggest that the p53-acetylation equilibrium may play
a role in primary neurulation in mammals.
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1 | INTRODUCTION
The neural tube is the embryonic precursor of the brain
and spinal cord, and formation of this structure is a criti-
cal process in embryonic development. In humans, neu-
ral tube closure occurs during the third and fourth weeks
after conception. Neural tube defects (NTDs) arise if clo-
sure is not completed, and the neuroepithelium remains
vulnerable to damage as it is not covered or protected.
The most common open NTDs include anencephaly and
spina bifida (Avagliano et al., 2018). Neurulation requires
the coordinated function of many gene products, as
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revealed by the large number (more than 290) of genetic
mouse mutant strains in which closure fails, resulting in
NTDs (Copp, Greene, & Murdoch, 2003; Harris &
Juriloff, 2007). Defects in mice closely parallel the
corresponding severe birth defects in humans which
affect 0.5–2 per 1,000 pregnancies (Greene & Copp, 2014;
Wallingford, Niswander, Shaw, & Finnell, 2013).
Although mouse mutants implicate a large number of
genes in neural tube closure, the molecular basis of NTDs
is not well understood in the majority of human cases.
Acetylation is a post-translational modification occur-
ring on histones and non-histone proteins that is capable
of regulating protein functions, localization, and stability
(Narita, Weinert, & Choudhary, 2018). A potential
requirement for acetylation in neural tube closure has
been suggested by the observation of cranial NTDs in
mouse embryos that carry even one null allele of p300, a
transcriptional co-activator that has potent histone
acetyltransferase (HAT) activity (Harris & Juriloff, 2007).
Interestingly, NTDs also occur at high frequency in null
embryos for Cited2 (Barbera et al., 2002), a
CBP/P300-interacting transactivator protein containing a
Glu/Asp-rich C-terminal domain. Null embryos for the
acetyltransferase gene Gcn5, die early in gestation with
developmental delay and extensive apoptosis in mesoder-
mal lineages (Bu, Evrard, Lozano, & Dent, 2007; Xu
et al., 2000). Double mutants of Gcn5 and p53 survive
longer and have reduced levels of apoptosis but they still
do not develop to the stage of neural tube closure
(Bu et al., 2007). A knock-in allele: Gcn5hat, was gener-
ated which incorporates point mutations in the catalytic
domain that result in specific ablation of HAT activity.
Homozygous Gcn5hat/hat embryos exhibit cranial NTDs,
without growth retardation or excessive apoptosis (Lin
et al., 2008). Thus, both decreased acetylation (HAT
mutants) and increased acetylation (Cited2) might be
associated with the development of NTDs. A possible role
for disturbed acetylation in NTDs also arises from consid-
eration of possible mechanisms underlying teratogenic
effects of antiepileptic drugs such as valproic acid (VPA),
whose use during pregnancy is a major risk factor for spi-
nal NTDs in humans (Wlodarczyk, Palacios, George, &
Finnell, 2012) and in animal models (Finnell, 1991;
Hughes, Greene, Copp, & Galea, 2018). VPA has efficient
histone deacetylase (HDAC) inhibitor activity, especially
in embryonic tissue susceptible to its toxicity (Menegola
et al., 2005).
In summary, acetylation represents an important
component of the complex network of post-translational
regulatory interactions. Evidence from mouse models
indicates a possible fundamental role during primary
neurulation events. It is assumed that acetylation also
occurs during human development (Goodman & Smolik,
2000), but is not known whether this alters with stage or
is affected in NTDs. In mice, the overall acetylation status
during neurulation stages has not been evaluated. Hence,
the aim of this study was to assess protein acetylation in
the context of early development of the mouse and
human central nervous system.
2 | MATERIALS AND METHODS
2.1 | Human samples
2.1.1 | Human cohort
Controls: formalin fixed, paraffin-embedded samples were
obtained from four healthy Caucasian women undergoing
legal termination of singleton pregnancy from 9 to
26 weeks of gestation (WG). Samples were obtained from
archival tissues from the Unit of Human Pathology of the
San Paolo Hospital Medical School, Milano, Italy. In this
group, fetuses did not exhibit any malformations. The NTD
case was from legal termination at 21 WG of a singleton
pregnancy affected by spina bifida in a Caucasian woman
with epilepsy who was treated with VPA. Termination of
pregnancy occurred at Department of Obstetrics and Gyne-
cology, Foundation MBBM, Monza, Italy.
2.1.2 | Immunohistochemistry
Immunohistochemistry was performed as previously
described (Avagliano et al., 2016) on 5 μm sections of
paraffin-embedded tissue using a Ventana system
(Ventana Medical Systems, Tucson, AZ) according to the
manufacturer's instructions. The primary antibody was
specific for acetyl-histone H4 (Acetyl-Histone H4 (Lys5)
(D12B3) Rabbit mAb #8647, Cell Signaling). Staining was
achieved using Ultraview Universal DAB detection kit
(Ventana Medical Systems) and counterstained with
hematoxylin. One fetus per stage was selected for this
study. Slides were immunostained in the same batch to
prevent technical variability and ensure identical condi-
tions for comparison.
2.1.3 | Counting
Images were digitalized and captured using a
NanoZoomer-XR Digital slide scanner (Hamamatsu,
Japan). After scanning the entire section, five randomly
selected fields of view per case and controls were photo-
graphed at ×20 magnification and analyzed using ImageJ
1.47v software (Bethesda, MD). Images were calibrated
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with a stage micrometer. H4 positive cells were calcu-
lated by counting within the five fields, by three opera-
tors blinded to experimental groups.
2.2 | Animal studies
2.2.1 | Animals
Animal studies were carried out under regulations of the
Animals (Scientific Procedures) Act 1986 of the UK Gov-
ernment, and according to guidance issued by the Medi-
cal Research Council, United Kingdom, in Responsibility
in the Use of Animals for Medical Research (July 1993).
Random-bred CD1 mice were purchased from Charles
River Laboratories, United Kingdom. Cited2 mutant, het-
erozygous and corresponding wild-type embryos were
obtained from four litters in each experimental group
and genotyped as previously reported (Barbera et al.,
2002). Animals were paired overnight and females
checked for vaginal plugs the following morning, desig-
nated embryonic day (E) 0.5. Embryos were dissected
from the uterus at desired developmental stages, morpho-
logically assessed, somites counted for staging, and frozen
at −80C for further analyses. Pifithrin-α (Komarov et al.,
1999) (2 mg/kg) or vehicle (PBS and saline) was adminis-
tered by intraperitoneal (i.p.) injection at E7.5, E8.5,
and E9.5.
2.2.2 | Western blot
Total proteins were extracted from embryos by standard
procedures (n = 3 embryos per pool per genotype). Fol-
lowing protein quantification, equal amounts of quanti-
fied extracts were used for western blot analyses as
previously described (de Castro et al., 2012) using anti-
bodies against acetylated lysines (Acetylated-Lysine Anti-
body #9441, Cell Signaling) or acetylated-p53 (Acetyl-p53
[Lys379-specific for mouse] Antibody #2570, Cell Signal-
ing). Positive bands were quantified, and analyses were
performed using GraphPad.
2.2.3 | Quantitative polymerase chain
reaction
RNA was extracted with TRIzol (Invitrogen, United King-
dom) as previously described (Fazio et al., 2017). First
strand cDNA was synthesized using a Superscript first-
strand Synthesis system (Invitrogen) following manufac-
turer's protocol. GreenER qPCR Supermix (Invitrogen)
with Biotaq DNA polymerase (Bioline, United Kingdom)
was used for quantitative polymerase chain reaction
(qPCR) analyses on a Fast System 7500 with SDS system
software (Applied Biosystems). Primers used were:
p53_Left: GCTTCTCCGAAGACTGGATG
p53_Right: CTTCACTTGGGCCTTCAAAA
GAPDH_Left: ATGACATCAAGAAGGTGGTG
GAPDH_Right: CATACCAGGAAATGAGCTTG
2.2.4 | Data analysis
For human data, acetyl-histone H4 positive cells were
counted as described and Mann–Whitney test was used
to compare cases and controls. For animal studies, t test
on qPCR data was applied. In both cases p ≤ 0.05 was set
as significant. GraphPad 6 software (San Diego, CA) and
Photoshop (Adobe Photoshop CC) software were utilized
for data analysis and figure preparation.
3 | RESULTS
To assess the overall histone acetylation profile during
early human spinal cord development, immunohisto-
chemical analysis was used to enable counting of
acetylated-histone H4 positive cells. At 9 WG, many posi-
tive cells could be detected in the developing spinal cord
(Figure 1a,b). The density of acetylated-histone H4
expressing cells decreased at 12 WG, and then remained
constant until at least 26 WG (Figure 1a,b). An NTD-
affected fetus (open spina bifida following VPA exposure,
21 WG) displayed a similar density of positive cells as
controls of comparable developmental stages.
Neural tube closure events occur at earlier stages of
development, 3–4 weeks, than in this group of human
fetuses. Therefore, for an assessment of the acetylation pro-
file during neurulation we turned to the mouse, in which
the neurulation process is similar to humans. In wild-type
embryos, global protein acetylation levels were compared,
using an antibody to acetylated lysine, shortly after initia-
tion of neural tube closure (E8.5), during cranial and upper
spinal closure (E9.5), and during the final stages of closure
when the low spine is formed (E10.5). This analysis
showed a dynamic pattern (Figure 1c), with an overall
increase of protein acetylation at E9.5. Intriguingly some
protein bands (e.g., 50 K protein in Figure 1c) showed a
distinct up-regulation of acetylation status at E9.5, showing
a temporal correlation with neurulation events.
We asked whether the observed changes in acetyl-
lysine staining are likely to reflect differential regulation
of acetylation. For this analysis, we used Cited2 mutants
as a positive control. Cited2 interacts with the known
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HAT, p300, hence we studied the acetylation profile of
mouse embryos from litters carrying a loss-of-function
mutation in Cited2 (Bhattacharya et al., 1999). Embryo
protein samples from E10.5 wild-type embryos were com-
pared with those from littermate Cited2 null embryos that
were either unaffected (closed brain) or with an NTD
(open brain; exencephaly). Intriguingly, a consistent dif-
ference in acetylation profile was observed in the three
pools of embryos. In particular, a band at around 50 KDa,
was absent from wild-type extracts, became visible in
unaffected Cited2−/− embryos, and appeared strongly
acetylated in Cited2−/− embryos in which neural tube clo-
sure had recently failed (Figure 1d).
Considering the importance of p53 in cell death and
differentiation during embryonic development (Van
Nostrand, Bowen, Vogel, Barna, & Attardi, 2017), and the
requirement for acetylation to prevent p53 degradation
(Reed & Quelle, 2014), we explored the possibility that
p53 is itself acetylated to a greater extent in affected
Cited2−/− mutants compared with wild-type embryos.
Protein extracts from wild-type and affected Cited2−/−
embryos were used for western blot analysis of
acetylated-p53 and, a 30% increase in normalized band
intensity was found in mutant samples (Figure 2a). Anal-
ysis of Trp53 mRNA abundance found no significant dif-
ference between wild-type, Cited2+/− and Cited2−/−
embryos at E9.5 (Figure 2b), showing that p53 abundance
was not misregulated at the transcriptional level. Hence,
acetylated-p53 shows a specific increase in abundance in
affected Cited2 mutant embryos.
We explored the possible functional relevance of p53
activity in the causation of NTDs in this mouse model.
FIGURE 1 Acetylation status is dynamic during human and mouse neural tube development. (a) Cells staining for acetylated-histone
H4 antibody are present in the normal developing human neural tube (Control), both at 9 and 20 WG. Note positive-staining cells also in the
spinal cord of a 21 WG individual with spina bifida (Case). Bar represents 250 μm. The orange line represent the level of histological
section (lumbar for all analyzed fetuses). (b) Quantification of acetylated-histone H4 staining: the median value is shown as a horizontal line
inside the boxes; upper and lower limits of the boxes represent upper and lower quartiles, respectively; whiskers represent the maximum and
minimum values. Among normal fetuses (controls), an early stage of gestation (9 WG) has a higher number of acetylated-histone H4 positive
cells per unit area than stages from 12 WG onward. The fetus with spina bifida (case) shows a similar density of positive cells as unaffected
individuals of a comparable stage. (c) Western blot demonstrates the dynamic acetylation profile of wild-type mouse embryos at different
developmental stages. Note the band at 50 KDa which has a peak of expression intensity at E9.5. (d) The acetylation profile of wild-type and
Cited2−/− embryos without (closed) and with (open) exencephaly. A 50 KDa band is upregulated in Cited2−/− embryos compared with wild-
type, with particularly strong acetylation in mutants with open neural tube
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Pregnant Cited2+/− females were treated by i.p. injection
either with vehicle (PBS and saline) or with a chemical
compound known to selectively inhibit p53 activity
(pifithrin-α) at three time-points (E7.5, E8.5, and E9.5).
On morphological evaluation of litters at E10.5, pifithrin-
α treatment was found to result in a significant reduction
in the frequency of NTDs in Cited2−/− embryos. Hence,
while 80% of control mutant embryos had exencephaly,
only 20% of pifithrin-α treated mutants had such defects
(p < 0.05). This experiment suggests a direct role of
increased p53 function in the development of NTDs in
Cited2 mutants which we hypothesize to be mediated
through altered acetylation.
4 | DISCUSSION
In contrast to N-terminal acetylation, which occurs co-
translationally on most proteins, selected proteins are
also subject to post-translational acetylation of specific
lysine residues. The lysine acetylation status of specific
proteins depends on a finely tuned equilibrium between
histone acetylases (HATs), which catalyze acetylation,
and HDACs, which remove acetyl groups (Glozak, Sen-
gupta, Zhang, & Seto, 2005).
Exposure of neurulation-stage mouse embryos to
pharmacological inhibitors of HDACs, such as VPA and
trichostatin A (TSA), can cause NTDs as well as skeletal
defects (Finnell, Waes, Eudy, & Rosenquist, 2002).
Pivotal work in chick embryos in vivo demonstrated that
TSA treatment induces NTDs with a complete failure of
neural tube closure, accompanied by morphological mod-
ifications in neuroepithelial cells and induction of
apoptosis (Murko et al., 2013). In previous studies, micro-
array approaches were used to analyze gene expression
alterations in somitic tissues of mouse embryos following
VPA exposure (Massa, Cabrera, Menegola, Giavini, &
Finnell, 2005). Cluster analysis showed major
misregulation of expression in the HDAC ontology group,
suggesting a possible role in the subsequent skeletal
defects. Modulation of acetylation was hypothesized to
mediate the effect of VPA on neurulation, and accord-
ingly increased acetylation of histone H4 in the caudal
neural tube was found (Menegola et al., 2005).
Considering the potential clinical relevance of altered
acetylation in NTDs and skeletal development, we sought
to ascertain the relevance of protein acetylation during
spinal cord development in human and mouse embryos.
Using different experimental approaches, our study
shows a dynamic profile of protein acetylation during the
stages of nervous system development in both humans
and mice. We also found p53-acetylation levels to be
abnormal in a mouse NTD model, the Cited2 gene knock-
out, in which occurrence of NTDs is associated with
increased acetylation. p53 was the first nonhistone pro-
tein to be shown to be subjected to acetylation modifica-
tion by HATs and HDACs, with important effects on its
stability and consequently on its transcriptional activity
(Brooks & Gu, 2011). Importantly, our data are in line
with a report of shRNA-mediated knock-down of
CITED2, resulting in increased acetylated-p53 in human
cancer cells (Wu, Sun, & Chao, 2011). Notably, rescue of
FIGURE 2 p53 acetylation
contribution to the Cited2−/− NTD
phenotype. (a) Quantification of
acetylated p53, normalized to actin
expression, shows an increase in
affected Cited2−/− embryos (three
embryos per pool per genotype were
used. Three replicates were performed).
Bars show standard deviation.
(b) Relative western blot analysis of
acetylated p53. (c) In contrast, total p53
gene expression (qPCR) does not differ
between Cited2 genotypes at E9.5.
(d) Chemical inhibition of p53 activity
using pifithrin-α results in a significant
decrease in the frequency of NTDs in
Cited2−/− embryos (Fisher's exact test:
*p = 0.023)
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the adverse effects of Cited2 loss of function was observed
following pifithrin-α-mediated inhibition of p53 activity,
suggesting a direct role for p53 in causing the
exencephaly observed in this model. In conclusion, this
study reports a dynamic profile of histone and protein
acetylation during CNS development and suggests
p53-acetylation equilibrium as fundamental for primary
neurulation in mammals.
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